Qiagen NV
QGEN
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.36B
Close$
$74.60
63.7% upside
Current Fair Value
63.7% upsideUndervalued by 63.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.36 Billion |
|---|---|
| Enterprise Value | $10.32 Billion |
| Dividend Yield | $2.64 (5.82%) |
| Earnings per Share | $2.04 |
| Beta | 0.61 |
| Outstanding Shares | 206,346,000 |
Return
| Return on Equity | 12.19% |
|---|---|
| Return on Assets | 6.95% |
| Return on Invested Capital | 9.59% |
Valuation & Multiples
| P/E Ratio | 23.27 |
|---|---|
| PEG | 313.23 |
| Price to Sales | 4.56 |
| Price to Book Ratio | 2.85 |
| Enterprise Value to Revenue | 4.91 |
| Enterprise Value to EBIT | 20.27 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.17 |
| Debt to Equity | 0.51 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.60
Average shareholder expectationRevenue Estimate
$527.50 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.62
Average shareholder expectationRevenue Estimate
$535.60 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 60.75% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.01%▼ 70.64% |
|---|---|
| Total Invested | $681,454▼ 99.99% |
| Investors Holding | 8▼ 356.00% |
ESG Score
No data
About Qiagen NV
5,654 employees
CEO: Thierry Bernard QIAGEN N.V. delivers comprehensive "sample to insight" solutions globally, enabling the transformation of biological materials into valuable molecular insights. Their extensive product portfolio addresses various stages of molecular anal...